anti cd8 apc cy7 Search Results


apc cy7 anti cd8  (Revvity)
99
Revvity apc cy7 anti cd8
Apc Cy7 Anti Cd8, supplied by Revvity, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/apc cy7 anti cd8/product/Revvity
Average 99 stars, based on 1 article reviews
apc cy7 anti cd8 - by Bioz Stars, 2026-03
99/100 stars
  Buy from Supplier
anti-human cd8 antibody pharmin, apc-cy™7  (Becton Dickinson)
90
Becton Dickinson anti-human cd8 antibody pharmin, apc-cy™7
CD19-1XX CAR-T cells show better anti-tumor activity in a pancreatic tumor model in vivo. (a) Timeline of of CD19 CAR-T treatment in mouse model. (b) Panc-1 CD19+ -bearing mice were treated with 1 × 10 6 CD19 CAR-T cells as indicated and tumor burden (tumor volume) of mice was measured at indicated days (n=4 mice each group). For mouse experiments, Control, PBS. (c) Tumor tissue from mice treated with indicated CAR-T cells. (d) Tumor tissue from mice treated with indicated CAR-T cells was sliced and stained with antibodies against human CD4 and <t>CD8</t> (n=4). The percentage of CD4 + (e) and CD8 + (f) T cells in tumor tissue from different groups of mice (n=4). All data are mean ± SEM.
Anti Human Cd8 Antibody Pharmin, Apc Cy™7, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti-human cd8 antibody pharmin, apc-cy™7/product/Becton Dickinson
Average 90 stars, based on 1 article reviews
anti-human cd8 antibody pharmin, apc-cy™7 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
anti-cd8-apc-cy7  (QuantoBio)
90
QuantoBio anti-cd8-apc-cy7
CD19-1XX CAR-T cells show better anti-tumor activity in a pancreatic tumor model in vivo. (a) Timeline of of CD19 CAR-T treatment in mouse model. (b) Panc-1 CD19+ -bearing mice were treated with 1 × 10 6 CD19 CAR-T cells as indicated and tumor burden (tumor volume) of mice was measured at indicated days (n=4 mice each group). For mouse experiments, Control, PBS. (c) Tumor tissue from mice treated with indicated CAR-T cells. (d) Tumor tissue from mice treated with indicated CAR-T cells was sliced and stained with antibodies against human CD4 and <t>CD8</t> (n=4). The percentage of CD4 + (e) and CD8 + (f) T cells in tumor tissue from different groups of mice (n=4). All data are mean ± SEM.
Anti Cd8 Apc Cy7, supplied by QuantoBio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti-cd8-apc-cy7/product/QuantoBio
Average 90 stars, based on 1 article reviews
anti-cd8-apc-cy7 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


CD19-1XX CAR-T cells show better anti-tumor activity in a pancreatic tumor model in vivo. (a) Timeline of of CD19 CAR-T treatment in mouse model. (b) Panc-1 CD19+ -bearing mice were treated with 1 × 10 6 CD19 CAR-T cells as indicated and tumor burden (tumor volume) of mice was measured at indicated days (n=4 mice each group). For mouse experiments, Control, PBS. (c) Tumor tissue from mice treated with indicated CAR-T cells. (d) Tumor tissue from mice treated with indicated CAR-T cells was sliced and stained with antibodies against human CD4 and CD8 (n=4). The percentage of CD4 + (e) and CD8 + (f) T cells in tumor tissue from different groups of mice (n=4). All data are mean ± SEM.

Journal: bioRxiv

Article Title: Balancing activation and costimulation of CAR tunes signaling dynamics and enhances therapeutic potency

doi: 10.1101/2022.03.01.482445

Figure Lengend Snippet: CD19-1XX CAR-T cells show better anti-tumor activity in a pancreatic tumor model in vivo. (a) Timeline of of CD19 CAR-T treatment in mouse model. (b) Panc-1 CD19+ -bearing mice were treated with 1 × 10 6 CD19 CAR-T cells as indicated and tumor burden (tumor volume) of mice was measured at indicated days (n=4 mice each group). For mouse experiments, Control, PBS. (c) Tumor tissue from mice treated with indicated CAR-T cells. (d) Tumor tissue from mice treated with indicated CAR-T cells was sliced and stained with antibodies against human CD4 and CD8 (n=4). The percentage of CD4 + (e) and CD8 + (f) T cells in tumor tissue from different groups of mice (n=4). All data are mean ± SEM.

Article Snippet: Anti-Human CD4 antibody (BD, Horizon, BUV395), anti-Human CD8 antibody (BD, Pharmin, APC-CY™7), anti-Human CD279(PD-1) antibody (Invitrogen, eBioscience, PE-Cyanine7), anti-Human CD223(LAG-3) antibody (Invitrogen, eBioscience,, Percp-efluor™710), anti-Human CD45RA antibody (Invitrogen, eBioscience, FITC), anti-Human CD62L antibody (Invitrogen, eBioscience, efluor450).

Techniques: Activity Assay, In Vivo, Staining

1XX modification of AXL CAR enhance its anti-tumor activity in a melanoma tumor model. (a) Timeline of of AXL CAR-T treatment in mouse model. (b) A375-bearing mice were treated with 2.5 × 10 6 AXL CAR-T cells and tumor burden (tumor volume) of mice were measured at indicated days (n=4, 5, 5 mice in respective groups). Control, PBS. (c) Tumor tissue of mice treated with indicated CAR-T cells (n=4, 5, 5). (d) The weight of tumors from different groups of mice (n=4, 5, 5). Number of CAR-T(e), CD4 + CAR-T cells (f) and CD8 + CAR-T cells (g) in spleen of mice 20 days post CAR-T infusion (n=5, 3). (h-k) Phenotype of CAR-T cells in the spleen of mice 20 days after CAR-T infusion as demonstrated by the percentage of T CM (CD45RA - CD62L + ) and T EFF (CD45RA + CD62L - ) cells (n=5, 3). All data are mean ± SEM.

Journal: bioRxiv

Article Title: Balancing activation and costimulation of CAR tunes signaling dynamics and enhances therapeutic potency

doi: 10.1101/2022.03.01.482445

Figure Lengend Snippet: 1XX modification of AXL CAR enhance its anti-tumor activity in a melanoma tumor model. (a) Timeline of of AXL CAR-T treatment in mouse model. (b) A375-bearing mice were treated with 2.5 × 10 6 AXL CAR-T cells and tumor burden (tumor volume) of mice were measured at indicated days (n=4, 5, 5 mice in respective groups). Control, PBS. (c) Tumor tissue of mice treated with indicated CAR-T cells (n=4, 5, 5). (d) The weight of tumors from different groups of mice (n=4, 5, 5). Number of CAR-T(e), CD4 + CAR-T cells (f) and CD8 + CAR-T cells (g) in spleen of mice 20 days post CAR-T infusion (n=5, 3). (h-k) Phenotype of CAR-T cells in the spleen of mice 20 days after CAR-T infusion as demonstrated by the percentage of T CM (CD45RA - CD62L + ) and T EFF (CD45RA + CD62L - ) cells (n=5, 3). All data are mean ± SEM.

Article Snippet: Anti-Human CD4 antibody (BD, Horizon, BUV395), anti-Human CD8 antibody (BD, Pharmin, APC-CY™7), anti-Human CD279(PD-1) antibody (Invitrogen, eBioscience, PE-Cyanine7), anti-Human CD223(LAG-3) antibody (Invitrogen, eBioscience,, Percp-efluor™710), anti-Human CD45RA antibody (Invitrogen, eBioscience, FITC), anti-Human CD62L antibody (Invitrogen, eBioscience, efluor450).

Techniques: Modification, Activity Assay